Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis

RCT in 612 patients refractory to biologic DMARDs, upadacitinib was superior to abatacept in change from baseline in DAS28-CRP at week 12 (mean change −2.52 and −2.00, respectively; p<0.001 non-inferiority; p<0.001 superiority) but was associated with more serious adverse events.

Source:

New England Journal of Medicine